Exhibits of the Same Type
Exhibit Details
产品：诺和期®（依柯胰岛素）
介绍：
诺和期®（依柯胰岛素）是全球首个胰岛素周制剂1，于2024年6月18日在中国获批上市，将在第7届进博会上中国首展。依柯胰岛素是诺和诺德首个在中国、欧盟与美国同步完成临床试验，同步递交新药上市申请的创新药物，真正实现全球同创2。
依柯胰岛素通过在循环中形成储库的创新策略显著延长半衰期，实现一周仅需一次注射，显著降低胰岛素的注射治疗负担1。3期临床研究结果证实，依柯胰岛素治疗，HbA1c降幅显著优于基础胰岛素日制剂（德谷胰岛素或甘精胰岛素U100/U300）3-6，更多比例的患者安全达标（达到HbA1c<7%且在过去12周未发生具有临床意义的或者严重的低血糖）3-6。
Product: Awiqli®(insulin icodec)
Introduction:
Awiqli®(insulin icodec) is the world’s first once-weekly basal insulin 1, was approved in China June 18, 2024, and will be exhibited in China for the first time at the 7th China International Import Expo (CIIE). Insulin icodec is the Novo Nordisk's first innovative drug to complete clinical trials and submit new drug applications simultaneously in China, European and United States, truly achieving global co-innovation2.
Insulin icodec significantly extends half-life through an innovative strategy to form a circulating depot, enabling only one injection per week , significantly reducing the burden of insulin injection1. Phase 3 clinical study results confirmed that with Insulin icodec , the reduction in HbA1c was significantly greater than daily basal insulin (insulin degludec or insulin glargine U100/U300) 3-6, and higher percentages of patients reach HbA1c <7% without hypoglycaemia( clinically significant or severe hypoglycaemia in the preceding 12 weeks)3-6.
参考文献 Reference
1. 张赛春, 等. 中华糖尿病杂志, 2024, 16(6): 611-615.
2. https://thepaper.cn/newsDetail_forward_27863610
3. Rosenstock J, et al. N Engl J Med. 2023; 389:297–308.
4. Lingvay I, et al. JAMA. 2023; 330:228–237.
5. Bajaj HS, et al. Ann Intern Med. 2023;176:1476-1485.
Philis-Tsimikas A, et al. Lancet Diabetes Endocrinol. 2023;11:414-425.